Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 26th Annual Global Healthcare Conference March 13, 2024 2:05 PM ET Company Participants Gilmore O'Neil - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone, and welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have ...

Affirm Holdings, Inc. (NASDAQ:AFRM) Wolfe Research FinTech Forum March 13, 2024 3:55 PM ET Company Participants Robert O’Hare - Senior Vice President of Finance Conference Call Participants Unidentified Company Representative [Call starts abruptly] yet, but we've been doing some work on it. We have a lot of investors that ask us about it. So, obviously of high interest. And you could see in the move in the stock, lot of focus and a lot of following by our investor and our client base as well. So, with that ...

PayPal Holdings, Inc. (NASDAQ:PYPL) Wolfe Research FinTech Forum March 13, 2024 10:20 AM ET Company Participants Jamie Miller - CFO Conference Call Participants Darrin Peller - Wolfe Research Darrin Peller Guys, thank you very much. All right. Good morning again everybody, for those of you, who I don't know. I'm Darrin Peller, I head up FinTech Research at Wolfe Research. Really happy to have Jamie with us today, from PayPal, who's the CFO of the company. And I think this is your first Investor Conference i ...

Lockheed Martin Corporation (NYSE:LMT) J.P. Morgan 2024 Industrials Conference Call March 13, 2024 10:15 AM ET Company Participants Jay Malave - Chief Financial Officer Conference Call Participants Seth Seifman - J.P. Morgan Seth Seifman Good morning, everyone. Welcome back to the aerospace defense track at the 2024 JPMorgan Industrials Conference. I'm Seth Seifman, the U.S. Aerospace Defense equity analyst. We are very grateful now and been very happy to have Lockheed Martin with us now. We have Jay Malave ...

Gilead Sciences, Inc. (NASDAQ:GILD) Barclays 26th Annual Global Healthcare Conference March 13, 2024 11:15 AM ET Company Participants Andy Dickinson - CFO Conference Call Participants Carter Gould - Barclays Carter Gould Good afternoon. Welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. biopharma. I am pleased to welcome Gilead Sciences to the stage. Joining us from the company, Andy Dickinson, CFO. Andy, you’re going to make some opening comments, and the ...

Summary of Colgate-Palmolive Company Conference Call Company Overview - **Company**: Colgate-Palmolive Company (NYSE:CL) - **Participants**: - John Hazlin - President, Hill's Pet Nutrition - Stan Sutula - Chief Financial Officer - Peter Grom - UBS Analyst Key Industry Insights - **Industry**: Pet Nutrition - **Growth Dynamics**: - Colgate has seen stronger organic revenue growth due to strategic initiatives, particularly in the Hill's division, which has experienced multiple years of double-digit organic sales growth [2][4][10] - The pet nutrition market has moderated post-COVID, with inflation impacting consumer buying behavior [15][16] Core Business Strategies - **Science-Driven Innovation**: - Hill's focuses on science-driven nutrition that leads to optimal health outcomes for pets, supported by veterinary endorsements [5][6] - Investment in media and advertising has increased brand awareness and household penetration [7][13] - **E-commerce Growth**: - E-commerce has become a significant growth channel for Hill's, which was previously underutilized [6] - **Advertising and Innovation**: - Increased investment in advertising has been crucial for driving growth, even during challenging times [10][11] - Continuous innovation in product offerings, such as the Derm Complete diet, has been a key focus [8] Market Challenges and Opportunities - **Market Slowdown**: - Post-COVID dynamics have led to softened volumes in the U.S. pet market, influenced by inflation and changes in pet adoption rates [15][16] - **Long-Term Growth Potential**: - Despite short-term challenges, the long-term outlook remains positive due to trends like the humanization of pets and premiumization of pet food [16][17] - Opportunities exist in under-indexed areas such as small dogs and cats, as well as therapeutic nutrition [21][22][31] Financial Performance and Projections - **Organic Growth Expectations**: - Hill's is expected to grow ahead of the company's long-term algorithm of 3% to 5%, with significant headroom for penetration in the U.S. market [30][32] - **Margin Compression**: - Hill's has faced margin compression due to raw material inflation, but pricing strategies and operational efficiencies are being implemented to recover margins [34][41] Capital Allocation and Strategic Investments - **Investment Focus**: - Colgate is committed to investing in capacity, R&D, and advertising to support long-term growth [24][61] - Recent acquisitions and new facilities are aimed at enhancing production capabilities and market reach [50][52] - **International Opportunities**: - International markets present significant growth potential, with low brand awareness and penetration in many regions [26][28] Conclusion - **Overall Outlook**: - Colgate-Palmolive's strategic focus on science-driven innovation, increased advertising, and capacity expansion positions Hill's for continued growth despite current market challenges [56][59] - **Commitment to Long-Term Growth**: - The company remains dedicated to leveraging its strengths in the pet nutrition market while navigating short-term challenges effectively [74][76]

Bristol-Myers Squibb Company (NYSE:BMY) Leerink Partners Global Biopharma Conference 2024 Conference Transcript March 13, 2024 10:00 AM ET Executives Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development Tim Power - Investor Relations Janet Barth - Investor Relations Analysts Dave Risinger - Leerink Partners Dave Risinger Great. So, good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners and it’s very much my pleasure to welc ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Leerink Partners Global Biopharma Conference March 13, 2024 10:40 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Christopher Fenimore - Chief Financial Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Thanks very much for being with us here today. I thought we could just start with the EYLEA franchise. Okay. We'll just jump right into it. Ryan Crowe Actually, David, if I could just read a forward-l ...

Key Points Industry and Company * **Company**: Air Products and Chemicals, Inc. (NYSE:APD) * **Industry**: Chemicals, Industrial Gases, Hydrogen Production Core Views and Arguments * **Large Projects and Financial Demands**: Air Products is investing $5-5.5 billion annually in capital expenditures (CapEx) for two large projects, with cash flow of $4 billion and $1.5 billion in dividends. This results in a cash burn of $2.5-2.8 billion for at least the next two years, raising leverage from 1.5 to 2.5x [2][3]. * **Financial Capacity and Leverage**: Air Products has the financial capacity to absorb the cash burn and maintain its A rating. The company aims to keep leverage between 1.5-2.5x, balancing opportunity and risk [3][6]. * **Louisiana Project Expansion**: The Louisiana project's scope was expanded from 5-5.5 million tons of CO2 sequestration to 10 million tons due to increased incentives under the Inflation Reduction Act. This expansion leverages existing infrastructure and reduces future costs [7][9]. * **Blue Ammonia Demand**: Air Products expects strong demand for blue ammonia in Japan and Korea for use in furnaces and marine shipping. This demand is driven by environmental regulations and corporate sustainability goals [16][17][18]. * **Green Hydrogen Demand**: Air Products believes there is strong demand for green hydrogen in Europe, driven by environmental regulations and the need to reduce carbon emissions. Green hydrogen is priced based on the cost of capital and the absence of raw material price escalation [41][44]. * **NEOM Project**: The NEOM project is a green hydrogen production facility in Saudi Arabia, serving European markets. Air Products is the general contractor, managing engineering, construction, and project delivery [31][37]. * **2024 Earnings**: Air Products faced challenges in 2024, including incorrect estimates of the Chinese economy and helium prices. However, the company remains committed to meeting its earnings expectations through cost control and productivity improvements [48][50]. Other Important Content * **Tax Credits**: Air Products can manage tax credits associated with carbon capture projects, as they can be received as cash in the first five years and traded thereafter [13][15]. * **Permitting Process**: The federal government's decision to give Louisiana primacy over the permitting process for Class 6 wells is a positive development for the Louisiana project, reducing the time frame for permit approval [23][25]. * **Geopolitical Risks**: Air Products acknowledges the potential impact of geopolitical events on project timelines, but remains confident in its ability to deliver projects on schedule [40].

Johnson & Johnson (NYSE:JNJ) Barclays 26th Annual Global Healthcare Conference March 13, 2024 10:45 AM ET Company Participants Peter Menziuso - Company Group Chairman, Johnson & Johnson Vision Conference Call Participants Matt Miksic - Barclays Matt Miksic Good morning, everybody. Thanks so much for joining us. I'm so pleased to have today Peter Menziuso. I like with a name like Peter, -- You think I'd be better at pronouncing complicated names. But a Company Group Chairman, Johnson & Johnson Vision, apprec ...